Back to News
Market Impact: 0.4
Amgen And AstraZeneca's IMDELLTRA Plus IMFINZI Cuts Death Risk By 58% In Small Cell Lung Cancer
Source: Nasdaq
Healthcare & Biotech
Amgen and AstraZeneca reported Phase 3 results showing that IMDELLTRA combined with IMFINZI significantly improved survival in patients with extensive-stage small cell lung cancer, an aggressive disease with historically poor outcomes. The report gives no numerical survival benefit or other trial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
AMGN0.75
AZN0.75
More News
- NOW 55% OFF: Rattled by Fed headlines? Meet the AI doubled the market’s return
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Cramer: I asked some tech insiders what to buy. They surprisingly said this drug stock
- The excitement around Moderna’s cancer vaccine is cooling. Here’s why.
- Moderna CEO Sees Cancer Vaccines Working Beyond Melanoma
- Bottoms Says Georgia Needs Pause on New Data Centers